Precise genome editing using CRISPR-Cas9 is a promising avenue for genetic disease research. However, there are a number of off-target editing issues to take into consideration. In this webinar, Dr. Matthew Coelho discusses findings from his recent publication in Nature Communications, "CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs." Attendees will learn more about:
For research use only. Not intended for use in diagnostic procedures. As such, unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any diagnostic use. Purchasers of RUO products manufactured and sold by IDT are solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
The speaker is not an employee or representative of AstraZeneca. All information presented on CRISPR GUARD is in the public domain.
Postdoctoral Fellow, Wellcome Sanger Institute
Dr. Matthew Coelho is a postdoctoral researcher in the Garnett laboratory focusing on functional genomics strategies to understand molecular pathways involved in sensitivity to cancer immunotherapies.
Dr. Coelho has gained prior expertise in cancer immunotherapy in the laboratory of Julian Downward at the Francis Crick Institute, as well as CRISPR and base editing technologies at AstraZeneca.